Otsuka to Acquire Avanir for $3.5 Billion

Dec 02, 2014

Reuters

Otsuka Holdings Co., based in Japan, plans to buy U.S.-based biopharmaceutical company Avanir Pharmaceuticals for about $3.5 billion, according to a Reuters article. The company seeks to expand its neurologic drug portfolio before expiration of a key drug patent.

The company seeks to build its product pipeline ahead of a "patent cliff" after April 2015, when its U.S. patent for schizophrenia drug Abilify expires and opens the door to generics. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments